Users of Avandia, appear to be at increased risk for a heart attack or heart failure. Regulators should seriously consider whether the drug should be allowed to remain on the market.
The pooled data from the trials indicated that Avandia, compared with controls, significantly increased the risk of heart attack by 42 percent (94 of 6,421 patients who received Avandia vs. 83 of 7,870 patients who received control therapy) and doubled the risk of heart failure (102 of 6,421 patients vs. 62 of 7,870 patients). Use of Avandia was not associated with a significant increase in risk of cardiovascular death.
For more information on this subject matter, please refer to the section on Drugs, Medical Devices, and Implants.